DNY59 Stifel has downgraded HilleVax ( NASDAQ: HLVX ) to hold following news that the company was discontinuing development of its norovirus vaccine candidate HIL-214 for infants due to disappointing data from its NEST-IN1 study. The investment bank noted HilleVax remains “well capitalized” and may proceed with developing either HIL-214 or HIL-216 for older/at-risk adults. However, it sees such a path as “a time/resource-intensive -- and non-registrational -- undertaking unlikely to yield much near-term support from investors in light of the NEST-IN1 data.
” Stifel added it saw “little opportunity for near-term price appreciation” and lowered its priced target to $3 from $34. More on HilleVax HilleVax slides after company's HIL-214 vaccine for infants fails to meet main goal Seeking Alpha’s Quant Rating on HilleVax Historical earnings data for HilleVax Financial information for HilleVax.
